Daniel Faissol | Principal Investigator, Center for Bioengineering, Executive Director, Predictive Design of Biologics
Lawrence Livermore National Laboratory

Dr. Faissol is the program lead for predictive design of biologics at Lawrence Livermore National Laboratory (LLNL) and the PI of the Generative Unconstrained Intelligent Drug Engineering program, which focuses on the computational design of antibodies and antigens. His primary research interest is in developing and integrating methods in machine learning, simulation, optimization and high throughput experiments to accelerate the design of biologics. He serves on the LLNL Data Science Institute Council and is the lead for the computational and data science area within the LLNL Bioengineering Center. Dr. Faissol joined LLNL after completing a PhD in Industrial and Systems Engineering from the Georgia Institute of Technology in 2008.

Appearances:

Pre-Congress Workshops - November 27 @ 14:00

Workshop A - Antibodies: Discovery vs Computational Design

Series of presentations followed by panel discussion

Computational design of antibodies - Dr Daniel Faissol, Principal Investigator, Center for Bioengineering, Executive Director, Predictive Design of Biologics, Lawrence Livermore National Laboratory

Discovery & development of broad-spectrum antibodies for Flu, COVID & RSV - Dr Phillip Lovanti, Sr. Director of R&D, Aridis Pharmaceuticals

Machine learning models for design of antibodies - Dr Sai Pooja Mahajan, Senior Scientist, Prescient Design, Genentech

Computational and artificial intelligence-based methods for antibody development - Dr Philip Kim, Professor, Principal Investigator, Department of Molecular Genetics, University of Toronto

How are NITAGs & HTAs thinking about novel antibody products? Richard Hughes, Partner, Epstein, Becker & Green, Professorial Lecturer in Law, The George Washington University Law School

Moderator: Lisa Purcell, Senior Vice President, Microbiology and Virology, Vir Biotechnology, Inc.